Get started
Keyword

capivasertib

Description: An anticancer drug that inhibits AKT proteins, investigated in oncology for treating advanced cancers.
Wikidata ID: wiki/Q27074756
OpenAlex ID: keywords/capivasertib
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
2019 · Peter Schmid, Jacinta Abraham, et al. · Journal of Clinical Oncology · 391
PDF
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
2020 · Nicholas C Turner, Belinda Kingston, et al. · The Lancet Oncology · 369
PDF
Targeting Akt in cancer for precision therapy
2021 · Hui Hua, Hongying Zhang, et al. · Journal of Hematology & Oncology · 242
PDF
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial
2020 · Robert H Jones, Angela Casbard, et al. · The Lancet Oncology · 230
PDF
Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial
2019 · Jeeyun Lee, Seung Tae Kim, et al. · Cancer Discovery · 228
AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?
2021 · Federica Martorana, Gianmarco Motta, et al. · Frontiers in Pharmacology · 214
PDF
Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer – A comprehensive review from chemotherapy to immunotherapy
2020 · Parham Jabbarzadeh Kaboli, Fatemeh Salimian, et al. · Pharmacological Research · 159
Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial
2019 · S. Hrebien, V. Citi, et al. · Annals of Oncology · 146
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial
2022 · Sacha J Howell, Angela Casbard, et al. · The Lancet Oncology · 145
PDF
Prospective experimental treatment of colorectal cancer patients based on organoid drug responses
2021 · S.N. Ooft, F. Weeber, et al. · ESMO Open · 142
PDF
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2 - and Non– BRCA1/2 -Mutant Cancers
2020 · Timothy A. Yap, Rebecca Kristeleit, et al. · Cancer Discovery · 128
Akt Pathway Inhibitors
2020 · Nne E. Uko, Osman F. Güner, et al. · Current Topics in Medicinal Chemistry · 118
Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer
2023 · Carla L. Alves, Henrik J. Ditzel · International Journal of Molecular Sciences · 115
PDF
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer
2020 · Lillian M. Smyth, Kenji Tamura, et al. · Clinical Cancer Research · 110
Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer
2024 · Iseult M Browne, Fabrice André, et al. · The Lancet Oncology · 105
“The emerging role of capivasertib in breast cancer”
2022 · Angeliki Andrikopoulou, Spyridoula Chatzinikolaou, et al. · The Breast · 104
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor
2020 · Kevin Kalinsky, Fangxin Hong, et al. · JAMA Oncology · 102
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer
2020 · M.P. Kolinsky, P. Rescigno, et al. · Annals of Oncology · 88
PDF
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population
2019 · N.C. Turner, E. Alarcón, et al. · Annals of Oncology · 88
Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID)
2020 · Simon J. Crabb, Gareth Griffiths, et al. · Journal of Clinical Oncology · 83
PDF
PI3K/AKT/mTOR inhibitors for hormone receptor-positive advanced breast cancer
2024 · Chunfang Hao, Yunchu Wei, et al. · Cancer Treatment Reviews · 79
PDF
Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer
2021 · Shannon N. Westin, Marilyne Labrie, et al. · Clinical Cancer Research · 79
PDF
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance
2023 · Mandy Lawson, Natalie Cureton, et al. · Cancer Research · 70
PDF
Endocrine and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update
2024 · Harold J. Burstein, Angela DeMichele, et al. · Journal of Clinical Oncology · 67
PDF
Qi-Li-Qiang-Xin Alleviates Isoproterenol-Induced Myocardial Injury by Inhibiting Excessive Autophagy via Activating AKT/mTOR Pathway
2019 · Cailian Fan, Xiyang Tang, et al. · Frontiers in Pharmacology · 58
PDF
Works count: 825
Citation count: 6,231
Year
Topic
Type